| Year |
Citation |
Score |
| 2023 |
Turkoz I, Wong J, Chee B, Siddiqui U, Knight RK, Richarz U, Correll CU. Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia. Therapeutic Advances in Psychopharmacology. 13: 20451253231200258. PMID 37786804 DOI: 10.1177/20451253231200258 |
0.32 |
|
| 2023 |
Lopena OJ, Alphs LD, Sajatovic M, Turkoz I, Sun L, Johnston KL, Sliwa JK, Najarian DM, Starr HL. Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis. The Journal of Clinical Psychiatry. 84. PMID 37756123 DOI: 10.4088/JCP.23m14788 |
0.36 |
|
| 2022 |
Williamson D, Turkoz I, Wajs E, Singh JB, Borentain S, Drevets WC. Adverse Events and Measurement of Dissociation after the First Dose of Esketamine in Patients with TRD. The International Journal of Neuropsychopharmacology. PMID 36525338 DOI: 10.1093/ijnp/pyac081 |
0.303 |
|
| 2022 |
Basu A, Benson C, Turkoz I, Patel C, Baker P, Brown B. Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) study. Journal of Managed Care & Specialty Pharmacy. 28: 1086-1095. PMID 36125055 DOI: 10.18553/jmcp.2022.28.10.1086 |
0.306 |
|
| 2022 |
Turkoz I, Daskiran M, Starr HL, Najarian D, Lopena O, Obando C, Keenan A, Benson C, Gopal S. Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections. Neuropsychiatric Disease and Treatment. 18: 1927-1937. PMID 36065384 DOI: 10.2147/NDT.S373725 |
0.314 |
|
| 2022 |
Alphs L, Baker P, Brown B, Fu DJ, Turkoz I, Nuechterlein KH. Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study. Schizophrenia Research. 248: 58-63. PMID 35939921 DOI: 10.1016/j.schres.2022.07.015 |
0.348 |
|
| 2022 |
Alphs L, Brown B, Turkoz I, Baker P, Fu DJ, Nuechterlein KH. The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder. Schizophrenia Research. 243: 86-97. PMID 35247794 DOI: 10.1016/j.schres.2022.02.019 |
0.367 |
|
| 2020 |
Nijs M, Wajs E, Aluisio L, Turkoz I, Daly E, Janik A, Borentain S, Singh JB, DiBernardo A, Wiegand F. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. The International Journal of Neuropsychopharmacology. PMID 32270176 DOI: 10.1093/Ijnp/Pyaa027 |
0.316 |
|
| 2019 |
Brown B, Turkoz I, Mancevski B, Mathews M. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Intervention in Psychiatry. PMID 31515972 DOI: 10.1111/Eip.12868 |
0.452 |
|
| 2019 |
Li N, Zhuo JM, Turkoz I, Mathews M, Feng Y, Tan W. A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics. Expert Opinion On Pharmacotherapy. 1-7. PMID 31393186 DOI: 10.1080/14656566.2019.1650022 |
0.309 |
|
| 2019 |
Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E. Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation. Neuropsychiatric Disease and Treatment. 15: 731-737. PMID 30962688 DOI: 10.2147/Ndt.S194264 |
0.435 |
|
| 2019 |
Lynum K, Turkoz I, Kim E. S32. Efficacy And Safety Of Paliperidone Palmitate Once-Monthly In Patients With Schizophrenia With Low, Moderate, And High Recent Disease Activity At Baseline Schizophrenia Bulletin. 45. DOI: 10.1093/Schbul/Sbz020.577 |
0.391 |
|
| 2018 |
Turkoz I, Sobel M, Alphs L. Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification. Pharmaceutical Statistics. PMID 30221459 DOI: 10.1002/Pst.1905 |
0.64 |
|
| 2018 |
Bell Lynum KS, Turkoz I, Kim E. Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia. Early Intervention in Psychiatry. PMID 29968279 DOI: 10.1111/Eip.12685 |
0.416 |
|
| 2018 |
Li H, Li Y, Feng Y, Zhuo J, Turkoz I, Mathews M, Tan W. Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study. Neuropsychiatric Disease and Treatment. 14: 1107-1117. PMID 29731633 DOI: 10.2147/Ndt.S157399 |
0.394 |
|
| 2018 |
Singh A, Gopal S, Kim E, Mathews M, Kern-Sliwa J, Turkoz I, Wooller A, Berlin J. Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International Clinical Psychopharmacology. PMID 29494348 DOI: 10.1097/Yic.0000000000000215 |
0.413 |
|
| 2018 |
Anderson AE, Marder S, Reise SP, Savitz A, Salvadore G, Fu DJ, Li Q, Turkoz I, Han C, Bilder RM. Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses. Schizophrenia Bulletin. PMID 29420822 DOI: 10.1093/Schbul/Sbx163 |
0.392 |
|
| 2017 |
Si T, Zhuo J, Turkoz I, Mathews M, Tan W, Feng Y. Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety. Expert Opinion On Pharmacotherapy. 1-11. PMID 29141463 DOI: 10.1080/14656566.2017.1401608 |
0.429 |
|
| 2017 |
Zhang H, Turkoz I, Zhuo J, Mathews M, Tan W, Feng Y. Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia. Advances in Therapy. PMID 29101715 DOI: 10.1007/S12325-017-0638-0 |
0.397 |
|
| 2017 |
Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone. The Journal of Clinical Psychiatry. PMID 28640988 DOI: 10.4088/Jcp.16M11308 |
0.384 |
|
| 2017 |
Scharfstein D, McDermott A, Díaz I, Carone M, Lunardon N, Turkoz I. Global sensitivity analysis for repeated measures studies with informative drop-out: A semi-parametric approach. Biometrics. PMID 28542799 DOI: 10.1111/Biom.12729 |
0.314 |
|
| 2017 |
Fu DJ, Turkoz I, Walling D, Lindenmayer JP, Schooler NR, Alphs L. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research. PMID 28454922 DOI: 10.1016/J.Schres.2017.04.004 |
0.313 |
|
| 2017 |
Brown B, Turkoz I, Yue Y, Alphs L. SA12. Baseline Demographics and Clinical Characteristics From a Prospective, Randomized, Open-Label Study of Paliperidone Palmitate Long-Acting Injection in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx023.011 |
0.427 |
|
| 2017 |
Sobel M, Turkoz I. Bayesian blinded sample size re-estimation Communications in Statistics - Theory and Methods. 47: 5916-5933. DOI: 10.1080/03610926.2017.1404097 |
0.614 |
|
| 2017 |
Si T, Zhuo J, Turkoz I, Mathews M, Katsu T, Feng Y. 522. The Difference in Clinical Outcome and Safety in Recent Diagnosis and Chronic Schizophrenic Disease after Paliperidone Palmitate 1 Month (PP1M) Treatment in Asian Patients Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.1130 |
0.368 |
|
| 2017 |
Zhang H, Turkoz I, Zhuo J, Matthews M, Katsu T, Feng Y. 521. Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.1129 |
0.393 |
|
| 2016 |
Bossie CA, Turkoz I, Alphs L, Mahalchick L, Fu DJ. Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder. The Journal of Nervous and Mental Disease. PMID 28005578 DOI: 10.1097/Nmd.0000000000000646 |
0.428 |
|
| 2016 |
Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L. Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. International Clinical Psychopharmacology. PMID 27434314 DOI: 10.1097/Yic.0000000000000141 |
0.424 |
|
| 2016 |
Fu DJ, Turkoz I, Simonson RB, Walling D, Schooler N, Lindenmayer JP, Canuso C, Alphs L. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder. Journal of Clinical Psychopharmacology. PMID 27322760 DOI: 10.1097/Jcp.0000000000000535 |
0.418 |
|
| 2016 |
Alphs L, Nasrallah HA, Bossie CA, Fu DJ, Gopal S, Hough D, Turkoz I. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. International Clinical Psychopharmacology. PMID 26974214 DOI: 10.1097/Yic.0000000000000125 |
0.412 |
|
| 2016 |
Alphs L, Fu DJ, Turkoz I. Paliperidone for the Treatment of Schizoaffective Disorder. Expert Opinion On Pharmacotherapy. PMID 26934062 DOI: 10.1517/14656566.2016.1161029 |
0.404 |
|
| 2016 |
Li H, Turkoz I, Zhang F. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study. Neuropsychiatric Disease and Treatment. 12: 15-24. PMID 26730193 DOI: 10.2147/Ndt.S83651 |
0.388 |
|
| 2015 |
Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L. Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone. Journal of Affective Disorders. 193: 381-390. PMID 26802315 DOI: 10.1016/J.Jad.2015.12.060 |
0.41 |
|
| 2014 |
Parke T, Dragalin V, Turkoz I, Marchenko O, Haynes V. Adaptive Design Applied to Identification of the Minimum Effective Dose in Schizophrenia: Simulations of Scientific and Commercial Value. Therapeutic Innovation & Regulatory Science. 48: 41-50. PMID 30231421 DOI: 10.1177/2168479013503825 |
0.34 |
|
| 2014 |
Sliwa JK, Fu DJ, Bossie CA, Turkoz I, Alphs L. Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate Bmc Psychiatry. 14. PMID 24559194 DOI: 10.1186/1471-244X-14-52 |
0.391 |
|
| 2013 |
Pandina G, Turkoz I, Bossie C. Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder. Journal of Affective Disorders. 151: 384-91. PMID 23849714 DOI: 10.1016/J.Jad.2013.01.053 |
0.35 |
|
| 2013 |
Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L. Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Annals of General Psychiatry. 12: 22. PMID 23845018 DOI: 10.1186/1744-859X-12-22 |
0.319 |
|
| 2013 |
Turkoz I, Fu DJ, Bossie CA, Sheehan JJ, Alphs L. Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression. Journal of Affective Disorders. 150: 17-22. PMID 23517884 DOI: 10.1016/J.Jad.2013.01.047 |
0.316 |
|
| 2013 |
Alphs L, Berwaerts J, Turkoz I. Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1597-9. PMID 23347971 DOI: 10.1016/J.Euroneuro.2012.12.006 |
0.324 |
|
| 2013 |
Pandina G, Bilder R, Turkoz I, Alphs L. Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder Schizophrenia Research. 143: 312-318. PMID 23276482 DOI: 10.1016/J.Schres.2012.11.031 |
0.372 |
|
| 2012 |
Alphs L, Olson WH, Turkoz I, Fastenau J, Hulihan J. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. The Journal of Clinical Psychiatry. 73: 1358; author reply 1. PMID 23140655 DOI: 10.4088/Jcp.12Lr07934 |
0.337 |
|
| 2012 |
Sliwa JK, Bossie CA, Fu DJ, Turkoz I, Alphs L. Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia. Neuropsychiatric Disease and Treatment. 8: 375-85. PMID 22956873 DOI: 10.2147/Ndt.S32581 |
0.384 |
|
| 2011 |
Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. Bmc Psychiatry. 11: 171. PMID 22034906 DOI: 10.1186/1471-244X-11-171 |
0.313 |
|
| 2010 |
Canuso CM, Turkoz I, Fu DJ, Bossie CA. Role of paliperidone extended-release in treatment of schizoaffective disorder. Neuropsychiatric Disease and Treatment. 6: 667-79. PMID 20957127 DOI: 10.2147/Ndt.S12612 |
0.434 |
|
| 2010 |
Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, Walling D, Lindenmayer JP. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. Journal of Clinical Psychopharmacology. 30: 487-95. PMID 20814330 DOI: 10.1097/Jcp.0B013E3181Eeb600 |
0.363 |
|
| 2010 |
Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, Schooler NR. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. The Journal of Clinical Psychiatry. 71: 587-98. PMID 20492853 DOI: 10.4088/Jcp.09M05564Yel |
0.362 |
|
| 2010 |
Canuso CM, Bossie CA, Amatniek J, Turkoz I, Pandina G, Cornblatt B. Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. Early Intervention in Psychiatry. 4: 64-78. PMID 20199482 DOI: 10.1111/J.1751-7893.2010.00165.X |
0.46 |
|
| 2010 |
Macfadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. International Clinical Psychopharmacology. 25: 75-82. PMID 20101185 DOI: 10.1097/Yic.0B013E3283347Cbf |
0.414 |
|
| 2010 |
Pandina GJ, Garibaldi GM, Revicki DA, Kleinman L, Turkoz I, Kujawa MJ, Mahmoud RA. Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial. International Clinical Psychopharmacology. 25: 51-9. PMID 20061962 DOI: 10.1097/Yic.0B013E3283320667 |
0.348 |
|
| 2010 |
Canuso CM, Turkoz I, Sheehan JJ, Bossie CA. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. Journal of Affective Disorders. 120: 193-9. PMID 19552963 DOI: 10.1016/J.Jad.2009.05.025 |
0.451 |
|
| 2010 |
Dunner DL, Bossie CA, Turkoz I, Canuso CM. Paliperidone extended-release (ER) in patients with schizoaffective disorder presenting with manic or depressive symptomatology Journal of Affective Disorders. 122. DOI: 10.1016/J.Jad.2010.02.078 |
0.316 |
|
| 2009 |
Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M, Mahmoud R. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disorders. 11: 827-39. PMID 19922552 DOI: 10.1111/J.1399-5618.2009.00761.X |
0.402 |
|
| 2009 |
Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extended-release for schizophrenia: Effects on symptoms and functioning in acutely ill patients with negative symptoms Schizophrenia Research. 113: 56-64. PMID 19560322 DOI: 10.1016/J.Schres.2009.05.021 |
0.432 |
|
| 2009 |
Pandina GJ, Revicki DA, Kleinman L, Turkoz I, Wu JH, Kujawa MJ, Mahmoud R, Gharabawi GM. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders. 118: 139-46. PMID 19321206 DOI: 10.1016/J.Jad.2009.02.019 |
0.373 |
|
| 2008 |
Turkoz I, Bossie CA, Dirks B, Canuso CM. Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia. Neuropsychiatric Disease and Treatment. 4: 949-58. PMID 19183785 DOI: 10.2147/Ndt.S3668 |
0.367 |
|
| 2008 |
Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. International Clinical Psychopharmacology. 23: 209-15. PMID 18545059 DOI: 10.1097/Yic.0B013E3282Fce651 |
0.405 |
|
| 2008 |
Alexopoulos GS, Canuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, Reynolds C. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 16: 21-30. PMID 17928573 DOI: 10.1097/Jgp.0B013E31813546F2 |
0.385 |
|
| 2008 |
Alphs L, Haskins JT, Turkoz I, Turner N, Schreiner A, Macfadden W. P.3.c.066 Adjunctive long-acting risperidone delays mood episode relapse in patients with frequently relapsing bipolar disorder European Neuropsychopharmacology. 18. DOI: 10.1016/S0924-977X(08)70650-3 |
0.345 |
|
| 2008 |
Alphs L, Turkoz I, Bossie C, Canuso C, Kujawa M. 20 – Placebo response in controlled clinical trials of patients with schizophrenia: A decade of differences Schizophrenia Research. 98: 41. DOI: 10.1016/J.Schres.2007.12.087 |
0.412 |
|
| 2008 |
Kujawa M, Turner N, Turkoz I, Macfadden W, Bossie C, Alphs L. Frequently relapsing bipolar disorder: Evidence for an effective treatment Schizophrenia Research. 98: 5. DOI: 10.1016/J.Schres.2007.12.005 |
0.339 |
|
| 2007 |
Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. The Journal of Nervous and Mental Disease. 195: 976-82. PMID 18091190 DOI: 10.1097/Nmd.0B013E31815C1982 |
0.437 |
|
| 2007 |
Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Annals of Internal Medicine. 147: 593-602. PMID 17975181 DOI: 10.7326/0003-4819-147-9-200711060-00003 |
0.392 |
|
| 2007 |
Docherty JP, Jones R, Turkoz I, Lasser RA, Kujawa M. Evaluation of a treatment manual for risperidone long-acting injectable. Community Mental Health Journal. 43: 267-80. PMID 17345148 DOI: 10.1007/S10597-006-9081-4 |
0.409 |
|
| 2006 |
Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, Rodriguez S, Gharabawi GM. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. The Journal of Clinical Psychiatry. 67: 1194-203. PMID 16965196 DOI: 10.4088/Jcp.V67N0804 |
0.453 |
|
| 2006 |
Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2505-13. PMID 16760927 DOI: 10.1038/Sj.Npp.1301218 |
0.388 |
|
| 2006 |
Gharabawi G, Canuso C, Pandina G, Bossie C, Kujawa M, Kosik-Gonzalez C, Turkoz I. P.8.a.053 A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder European Neuropsychopharmacology. 16: S562. DOI: 10.1016/S0924-977X(06)70794-5 |
0.342 |
|
| 2006 |
Gharabawi GM, Bossie CA, Bouhours P, Turkoz I, Kujawa M. P.3.a.048 Insight in schizophrenia: clinical correlates and relationship to functioning European Neuropsychopharmacology. 16. DOI: 10.1016/S0924-977X(06)70477-1 |
0.362 |
|
| 2005 |
Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clinical Therapeutics. 27: 1930-41. PMID 16507379 DOI: 10.1016/J.Clinthera.2005.12.005 |
0.375 |
|
| 2005 |
Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophrenia Research. 77: 119-28. PMID 15913963 DOI: 10.1016/J.Schres.2005.03.008 |
0.32 |
|
| 2005 |
Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. The Journal of Clinical Psychiatry. 66: 205-12. PMID 15705006 DOI: 10.4088/Jcp.V66N0208 |
0.367 |
|
| 2004 |
Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. The Journal of Clinical Psychiatry. 65: 386-94. PMID 15096079 DOI: 10.4088/Jcp.V65N0315 |
0.383 |
|
| 2004 |
Grossman F, Okamoto A, Turkoz I, Gharabawi G. Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias. Journal of the American Geriatrics Society. 52: 852-3. PMID 15086685 DOI: 10.1111/J.1532-5415.2004.52230_12.X |
0.304 |
|
| 2003 |
Gharabawi G, Turkoz I, Pandina G. Oral risperidone + lorazepam versus IM haloperidol + lorazepam in the emergency treatment of acute psychosis in schizophrenia and schizoaffective disorder Schizophrenia Research. 60: 284. DOI: 10.1016/S0920-9964(03)80463-2 |
0.428 |
|
| Show low-probability matches. |